Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper reviews the role of pharmacokinetic/pharmacodynamic modeling in drug development, emphasizing its application for drug dosing guidance, safety resolution, and therapeutic monitoring improvement, without presenting new clinical results.

This study found that the optimized finasteride-loaded lyophilized tablets using a self-nanoemulsifying drug delivery system improved bioavailability in human volunteers compared to the marketed finasteride product.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This report advances the hypothesis that finasteride and dutasteride inhibit 5α-reductase activities, potentially altering steroid metabolism and increasing the risk of insulin resistance, diabetes, and vascular disease.

This study suggests a weak association between male-pattern baldness and some coronary heart disease risk factors, but does not support it as a strong indicator of coronary risk.

Finasteride helped treat a 28-year-old's facial skin condition.

This randomized clinical trial found that vitamin D supplementation did not significantly alter anthropometric or metabolic parameters in obese, insulin-resistant, and vitamin D-deficient women with polycystic ovary syndrome, whereas metformin effectively reduced body weight, BMI, waist circumference, total body fat, and serum glucose levels.

In this study, co-administration of finasteride with oral testosterone undecanoate in young men with induced hypogonadism had no significant effect on serum testosterone or dihydrotestosterone levels, likely due to TU's unique absorption route.

This study found that using nanoporous silica entrapped lipid-drug complexes enhanced the solubility and bioavailability of dutasteride in beagle dogs.

This study found that co-administering glucocorticoids with 5α-reductase inhibitors exacerbated the adverse metabolic effects of glucocorticoids in healthy men.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.

This article discusses post-finasteride syndrome as a distinct syndrome related to prolonged use of 5α-steroid reductase inhibitors, noting persistent side effects even after discontinuation and no new research results are reported.

This study found that finasteride may reduce inappropriate sexual behaviors in geriatric patients with vascular dementia and benign prostate hyperplasia without serious side effects, though some patients required additional medications.

This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

In this study, a new Finasteride conjugate showed stronger inhibition of 5α-reductase and similar reduction of prostate hyperplasia in rats compared to Finasteride, with potentially improved toxicity.

This meta-analysis involving over 3.7 million patients found that diabetes mellitus is associated with a reduced risk of developing prostate cancer, although significant heterogeneity exists among studies; however, a family history of prostate cancer was linked to a higher risk.

This study found that Medicare patients with benign prostatic hyperplasia had high adherence to 5-alpha reductase inhibitor therapy, which was associated with a reduced risk of needing surgical intervention.

This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

This review discusses the efficacy and safety of oral finasteride for treating male pattern baldness and the potential persistent side effects, but no new results are reported.

Among a Han Chinese cohort, this study found that a higher genetic risk score was linked to increased susceptibility to BPH, larger prostate size, reduced effectiveness of 5ARI treatment, and a higher risk of undergoing TURP.

This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.

In this study, the use of 5-α reductase inhibitors was not associated with an increased risk of anaemia compared to α-blockers in men with benign prostatic hyperplasia.

This review discusses the occurrence of persistent sexual, physical, neurological, and psychiatric side effects known as post-finasteride syndrome after 5x-reductase inhibitor treatment, and emphasizes the importance of evaluating these risks for patients with benign prostatic hyperplasia or androgenic alopecia.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

In this study, paternal exposure to finasteride prior to or during pregnancy was linked to a majority of normal full-term births, although some cases resulted in abortions, aligning with previous animal study findings.

This research examined krill oil's effects on benign prostatic hyperplasia and found that it inhibited the growth of prostate cells in vitro and reduced prostate size and weight in a BPH rat model, suggesting potential as a prophylactic or therapeutic agent for BPH.

This randomized, placebo-controlled trial reported that USPlus PRO saw palmetto extract significantly improved lower urinary tract symptoms, including voiding, incomplete emptying, and weak stream, as well as sexual function in males over 12 weeks, while maintaining a favorable safety profile.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.